睾丸切除术治疗的前列腺转移性疾病患者的循环睾酮、前列腺核雄激素受体与疾病进展时间

Circulating testosterone, prostatic nuclear androgen receptor and time to progression in patients with metastatic disease of the prostate treated by orchiectomy.

作者信息

van Aubel O G, Bolt-de Vries J, Blankenstein M A, de Jong F H, Schröder F H

机构信息

Department of Urology, Erasmus University, Rotterdam, The Netherlands.

出版信息

Urol Res. 1989;17(2):99-102. doi: 10.1007/BF00262028.

DOI:10.1007/BF00262028

PMID:2734984

Abstract

The content of nuclear androgen receptors (ARn) in prostatic carcinoma biopsies is not predictive for the duration of response of the tumor to endocrine therapy. Recently pre-treatment plasma testosterone has been suggested to be predictive in this respect. Therefore, pre-treatment plasma testosterone (T) and sex hormone binding globulin (SHBG) levels were studied in 31 patients aged 72 +/- 10 years (range: 45-87) with stage D2 carcinoma of the prostate treated by orchiectomy. In 26 of these patients, the ARn level of the carcinoma was also known (61 +/- 41 fmol/mg protein; range 0-169). Plasma T levels (mean: 13.7 +/- 6.1 nmol/l) varied widely (range: 2.4-25.4), as did plasma SHBG (32.5 +/- 19.3 nmol/l; range 4.4-78.8), and time to progression (TTP; 14.6 +/- 11.2 months; range 1-48). Plasma T was found to be correlated to age (Rs = 0.537; P less than 0.01) and TTP (Rs = 0.4495; P less than 0.02). Tissue ARn and plasma SHBG did not correlate to any of the parameters studied.

摘要

前列腺癌活检中核雄激素受体（ARn）的含量不能预测肿瘤对内分泌治疗的反应持续时间。最近有人提出治疗前血浆睾酮在这方面具有预测性。因此，我们研究了31例年龄在72±10岁（范围：45 - 87岁）、采用睾丸切除术治疗的D2期前列腺癌患者的治疗前血浆睾酮（T）和性激素结合球蛋白（SHBG）水平。在这些患者中，有26例患者的癌组织ARn水平也已知（61±41 fmol/mg蛋白；范围0 - 169）。血浆T水平（均值：13.7±6.1 nmol/l）变化很大（范围：2.4 - 25.4），血浆SHBG水平（32.5±19.3 nmol/l；范围4.4 - 78.8）以及疾病进展时间（TTP；14.6±11.2个月；范围1 - 48）也是如此。发现血浆T与年龄相关（Rs = 0.537；P < 0.01）以及与TTP相关（Rs = 0.4495；P < 0.02）。组织ARn和血浆SHBG与所研究的任何参数均无相关性。